版權(quán)說明：本文檔由用戶提供并上傳，收益歸屬內(nèi)容提供方，若內(nèi)容存在侵權(quán)，請進行舉報或認領(lǐng)
文檔簡介
ModernManagementofProlongedRuptureofMembranesJosephR.BiggioJr.,M.D.DepartmentofObstetrics&GynecologyDivisionofMaternal-FetalMedicineUniversityofAlabamaatBirminghamModernManagementofProlongedPROMAmniorrhexispriortoonsetofactivelaborregardlessofgestationalagePrematureRuptureofMembranesPROMAmniorrhexispriortoonsePPROMAmniorrhexis<37weeks’gestationalagepriortoonsetofactivelaborPretermPrematureRuptureofMembranesPPROMAmniorrhexis<37weeks’LatencyIntervalfromRuptureofMembranestoOnsetofActiveLaborLatencyIntervalfromRuptureoDiagnosisHistoryAvoiddigitalexamVaginalPoolNitrazinePaperFerningUltrasoundAmniocentesis/DyeStudyDiagnosisHistoryPROMnearTermManagementgestationalagedependentInductionvs.awaitingspontaneouslaborAntibioticprophylaxisperACOG/CDCrecommendationsPROMnearTermManagementgestaInductionvs.ExpectantManagement>5,000womenrandomizedOxytocin,PGE2orexpectantmanagementupto4daysNodifferenceincesareansectionorneonatalinfectionLesschorioamnionitisininductionwithoxytocingroupHannah,NEJM,1996Inductionvs.ExpectantManageEpidemiologyofPretermBirthPPROMSpontaneousPretermDelivery IndicatedPretermDelivery 28%46%26%Andrews,1995EpidemiologyofPretermBirthPPPROM
RiskFactorsLower/UpperGenitalTractInfectionProteasesProstaglandinsHistoryofPPROMIncompetentCervixAbruptionPolyhydramniosMultipleGestationSmokingPPROM
RiskFactorsLower/UpperPPROM
ComplicationsMaternal/FetalInfectionPrematureLaborandDeliveryUmbilicalCordProlapseFetalHypoxia2oCordCompressionIncreasedRateofCesareanSectionIntrauterineGrowthRestrictionAbruptionStillbirthPPROM
ComplicationsMaternal/FePPROM
StandardManagementConfirmationofDiagnosisVerificationofGestationalAgeR/OLabor/Infection/FetalCompromiseAvoidDigitalVaginalExaminationsInHospitalObservationBedrestPPROM
StandardManagementConfiPPROM
Latency
GestationalAge(Weeks)%PatientswithLatency>1Week2550750Wilson,Obstetrics&Gynecology,1982PPROM
LatencyGestationalAgePPROM
VaginalExaminationGestationalAge(Weeks)2015105LatencyDaysNoExamExamLewis,Obstetrics&Gynecology,1992PPROM
VaginalExaminationGestaPreviablePPROM<24weeksPoorprognosisforsuccessfuloutcomeOutcomemaybedifferentforspontaneousvs.iatrogenicPreviablePPROM<24weeksPreviablePPROM
Complications
UterineInfectionPulmonaryHypoplasiaLimbCompressionDeformitiesIntrauterineGrowthRestrictionPreviablePPROM
ComplicationsPreviablePPROM
OutcomesPreviablePPROM
OutcomesPPROM
ManagementIssues
TimingofDeliveryTocolysisAntibioticsSteroidsAmniocentesisObservationvs.InductionFetalLungMaturityTestingFetalSurveillancePPROM
ManagementIssuesTimingTimingofDeliveryTimingofDeliveryNeonatalMorbidity/Mortality
UAB(1995-1996)%NeonatalMorbidity/Mortality
URNICUSurvivalandMorbidityData(1995-1996)%NeonatesRNICUSurvivalandMorbidityDTocolysisTocolysisPPROM
TocolysisWeiner,AJOG,1988PPROM
TocolysisWeiner,AJOG,1PPROM
TocolysisGarite,AJOG,1987PPROM
TocolysisGarite,AJOG,1AntibioticsAntibioticsPretermLabor
ChorioamnionColonization0￡30weeks31-34weeks34-36weeks337weeks255075%PatientsColonizedSpontaneousPretermLaborIndicatedCassell,1993PretermLabor
ChorioamnionColPPROM
AntibioticTherapyReductionMaternal/PerinatalInfectionProlongLatencyPeriodImproveNeonatalOutcomePPROM
AntibioticTherapyReductAntibiotic:PPROM
NIH-MFMNetworkStudyPPROMbetween24and32weeksIVampicillinanderythromycinfor48hOralamoxicillin/erythromycinfor5daysIdentificationandRxofGBScarriersTocolysisandcorticosteroidsprohibited
Mercer,JAMA,1997Antibiotic:PPROM
NIH-MFMNetwAntibiotic:
NIH-MFMNetworkStudyNeonatalMorbidity***Antibiotic:
NIH-MFMNetworkAntibiotic:LatencyPeriod
NIH-MFMNetworkStudyAntibiotic:LatencyPeriod
NIHPPROM
AntibioticTherapyOptimalAntibioticRegimenRoute/DurationofAdministrationPPROM
AntibioticTherapyOptimaAntibiotics&PPROM:SummaryReductioninmaternalinfectiousmorbidityReductioninbirths<48hand<7dReductioninneonatalinfectiousmorbidityReductioninneonatesrequiringNICUandventilation>28dKenyon,CochraneLibrary,1999Antibiotics&PPROM:SummaryReAntibiotics&PPROM:SummaryNoclearreductioninperinataldeathNoclearreductionincerebralabnormalitiesKenyon,CochraneLibrary,1999Antibiotics&PPROM:SummaryNoAmniocentesisAmniocentesisPPROM
AmnioticFluidCultureGroupBStreptococcus 20%Gardnerellavaginalis 17%Peptostreptococcus 11%Fusobacteria 10%Bacteroidesfragilis 9%OtherStreptococci 9%Bacteroidessp. 5% PPROM
AmnioticFluidCultureGUtilityofAmniocentesisConfirm/RefutediagnosisofchorioamnionitisGlucose<15mg/dLCultureGramstainLungmaturitytestingUtilityofAmniocentesisConfirCorticosteroidsCorticosteroidsCorticosteroidsforFLMBetamethasoneDexamethasoneCorticosteroidsforFLMBetametPPROM
CorticosteroidsBlockTaeuschPapageorgiouYoungGariteCollaborativeIamsNelsonSimpsonMorales4317173880153382211212126241937801353546105124AuthorSteroidsControlEffectonRDSNumberofPatientsPPROM
CorticosteroidsBlock4326PPROM
CorticosteroidsCrowley,Ob/GynClinics,1992*PPROM
CorticosteroidsCrowley,PPROM
Corticosteroids+Antibiotics*Lewis,Obstetrics&Gynecology,1996PPROM
Corticosteroids+Antibi1994NIHConsensusConference:
CorticosteroidsinPPROMCorticosteroidsreduceincidence/severityofRDS,IVHBenefitsinPPROMupto30-32weeksNosignificantadverseoutcomesforcorticosteroiduseinPPROMImpactlessthanwithintactmembranes1994NIHConsensusConference:Observationvs.InductionObservationvs.InductionNeonatalMorbidity/Mortality
UAB(1995-1996)%NeonatalMorbidity/Mortality
UPPROM
Observationvs.InductionMercer,AJOG,1993**PPROM
Observationvs.InductioPPROM
ObservationvsInductionCox,Obstetrics&Gynecology,1995PPROM
ObservationvsInductionFetalLungMaturityTestingFetalLungMaturityTestingFetalLungMaturation
BiologicMarkers8642004268202428323640GestationalAge(weeks)L:SRatio%PhospholipidL:SPIPG10FetalLungMaturation
BiologicFetalLungMaturityEvaluationinVaginalPoolSpecimenL:SRatio NotReliableTDX:FLMAssay NotValidatedPG Useful
FetalLungMaturityEvaluationFetalSurveillanceFetalSurveillancePPROM
FetalSurveillanceDailyNon-StressTest(NST)VariablesTachycardiaLossofreactivityBiophysicalProfile(BPP)ContractionStressTest(CST)PPROM
FetalSurveillanceDailySummarySummaryUABManagementofPPROMPPROM34weeksDeliverPreviablePROMOutpatientobservationAntibioticprophylaxisOptionoftermination<22wkAdmissionatviability
UABManagementofPPROMPPROMPPROM23weeks,<34weeksAntibioticprophylaxis:Amoxicillin500tidx10d,Azithromycin1gmd1&d51courseBetamethasoneif<32weeksTestforpoolPGweeklybeginningat32weeksDeliverat34-35weeksUABManagementofPPROMPPROM23weeks,<34weeksUABModernManagementofProlongedRuptureofMembranesJosephR.BiggioJr.,M.D.DepartmentofObstetrics&GynecologyDivisionofMaternal-FetalMedicineUniversityofAlabamaatBirminghamModernManagementofProlongedPROMAmniorrhexispriortoonsetofactivelaborregardlessofgestationalagePrematureRuptureofMembranesPROMAmniorrhexispriortoonsePPROMAmniorrhexis<37weeks’gestationalagepriortoonsetofactivelaborPretermPrematureRuptureofMembranesPPROMAmniorrhexis<37weeks’LatencyIntervalfromRuptureofMembranestoOnsetofActiveLaborLatencyIntervalfromRuptureoDiagnosisHistoryAvoiddigitalexamVaginalPoolNitrazinePaperFerningUltrasoundAmniocentesis/DyeStudyDiagnosisHistoryPROMnearTermManagementgestationalagedependentInductionvs.awaitingspontaneouslaborAntibioticprophylaxisperACOG/CDCrecommendationsPROMnearTermManagementgestaInductionvs.ExpectantManagement>5,000womenrandomizedOxytocin,PGE2orexpectantmanagementupto4daysNodifferenceincesareansectionorneonatalinfectionLesschorioamnionitisininductionwithoxytocingroupHannah,NEJM,1996Inductionvs.ExpectantManageEpidemiologyofPretermBirthPPROMSpontaneousPretermDelivery IndicatedPretermDelivery 28%46%26%Andrews,1995EpidemiologyofPretermBirthPPPROM
RiskFactorsLower/UpperGenitalTractInfectionProteasesProstaglandinsHistoryofPPROMIncompetentCervixAbruptionPolyhydramniosMultipleGestationSmokingPPROM
RiskFactorsLower/UpperPPROM
ComplicationsMaternal/FetalInfectionPrematureLaborandDeliveryUmbilicalCordProlapseFetalHypoxia2oCordCompressionIncreasedRateofCesareanSectionIntrauterineGrowthRestrictionAbruptionStillbirthPPROM
ComplicationsMaternal/FePPROM
StandardManagementConfirmationofDiagnosisVerificationofGestationalAgeR/OLabor/Infection/FetalCompromiseAvoidDigitalVaginalExaminationsInHospitalObservationBedrestPPROM
StandardManagementConfiPPROM
Latency
GestationalAge(Weeks)%PatientswithLatency>1Week2550750Wilson,Obstetrics&Gynecology,1982PPROM
LatencyGestationalAgePPROM
VaginalExaminationGestationalAge(Weeks)2015105LatencyDaysNoExamExamLewis,Obstetrics&Gynecology,1992PPROM
VaginalExaminationGestaPreviablePPROM<24weeksPoorprognosisforsuccessfuloutcomeOutcomemaybedifferentforspontaneousvs.iatrogenicPreviablePPROM<24weeksPreviablePPROM
Complications
UterineInfectionPulmonaryHypoplasiaLimbCompressionDeformitiesIntrauterineGrowthRestrictionPreviablePPROM
ComplicationsPreviablePPROM
OutcomesPreviablePPROM
OutcomesPPROM
ManagementIssues
TimingofDeliveryTocolysisAntibioticsSteroidsAmniocentesisObservationvs.InductionFetalLungMaturityTestingFetalSurveillancePPROM
ManagementIssuesTimingTimingofDeliveryTimingofDeliveryNeonatalMorbidity/Mortality
UAB(1995-1996)%NeonatalMorbidity/Mortality
URNICUSurvivalandMorbidityData(1995-1996)%NeonatesRNICUSurvivalandMorbidityDTocolysisTocolysisPPROM
TocolysisWeiner,AJOG,1988PPROM
TocolysisWeiner,AJOG,1PPROM
TocolysisGarite,AJOG,1987PPROM
TocolysisGarite,AJOG,1AntibioticsAntibioticsPretermLabor
ChorioamnionColonization0￡30weeks31-34weeks34-36weeks337weeks255075%PatientsColonizedSpontaneousPretermLaborIndicatedCassell,1993PretermLabor
ChorioamnionColPPROM
AntibioticTherapyReductionMaternal/PerinatalInfectionProlongLatencyPeriodImproveNeonatalOutcomePPROM
AntibioticTherapyReductAntibiotic:PPROM
NIH-MFMNetworkStudyPPROMbetween24and32weeksIVampicillinanderythromycinfor48hOralamoxicillin/erythromycinfor5daysIdentificationandRxofGBScarriersTocolysisandcorticosteroidsprohibited
Mercer,JAMA,1997Antibiotic:PPROM
NIH-MFMNetwAntibiotic:
NIH-MFMNetworkStudyNeonatalMorbidity***Antibiotic:
NIH-MFMNetworkAntibiotic:LatencyPeriod
NIH-MFMNetworkStudyAntibiotic:LatencyPeriod
NIHPPROM
AntibioticTherapyOptimalAntibioticRegimenRoute/DurationofAdministrationPPROM
AntibioticTherapyOptimaAntibiotics&PPROM:SummaryReductioninmaternalinfectiousmorbidityReductioninbirths<48hand<7dReductioninneonatalinfectiousmorbidityReductioninneonatesrequiringNICUandventilation>28dKenyon,CochraneLibrary,1999Antibiotics&PPROM:SummaryReAntibiotics&PPROM:SummaryNoclearreductioninperinataldeathNoclearreductionincerebralabnormalitiesKenyon,CochraneLibrary,1999Antibiotics&PPROM:SummaryNoAmniocentesisAmniocentesisPPROM
AmnioticFluidCultureGroupBStreptococcus 20%Gardnerellavaginalis 17%Peptostreptococcus 11%Fusobacteria 10%Bacteroidesfragilis 9%OtherStreptococci 9%Bacteroidessp. 5% PPROM
AmnioticFluidCultureGUtilityofAmniocentesisConfirm/RefutediagnosisofchorioamnionitisGlucose<15mg/dLCultureGramstainLungmaturitytestingUtilityofAmniocentesisConfirCorticosteroidsCorticosteroidsCorticosteroidsforFLMBetamethasoneDexamethasoneCorticosteroidsforFLMBetametPPROM
CorticosteroidsBlockTaeuschPapageorgiouYoungGariteCollaborativeIamsNelsonSimpsonMorales4317173880153382211212126241937801353546105124AuthorSteroidsControlEffectonRDSNumberofPatientsPPROM
CorticosteroidsBlock4326PPROM
CorticosteroidsCrowley,Ob/GynClinics,1992*PPROM
CorticosteroidsCrowley,PPROM
Corticosteroids+Antibiotics*Lewis,Obstetrics&Gynecology,1996PPROM
Corticosteroids+Antibi1994NIHConsensusConference:
CorticosteroidsinPPROMCorticosteroidsreduceincidence/severityofRDS,IVHBenefitsinPPROMupto30-32weeksNosignificantadverseoutcomesforcorticosteroidusein
溫馨提示
- 1. 本站所有資源如無特殊說明，都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等，如果需要附件，請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙，網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽，若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間，僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理，對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯，并不能對任何下載內(nèi)容負責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當內(nèi)容，請與我們聯(lián)系，我們立即糾正。
- 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 新人教版七年級數(shù)學(xué)上冊1.5.1《乘方》聽評課記錄1
- 門禁安裝施工方案
- 歷史教研組聽評課記錄表
- 初一寫過的數(shù)學(xué)試卷
- 美麗鄉(xiāng)村籃球場施工方案
- 一年級語文上聽評課記錄
- 聽評課記錄三年級上
- 語文一年級聽評課記錄
- 2025年度智慧醫(yī)療系統(tǒng)分包服務(wù)協(xié)議
- 蘇科版數(shù)學(xué)七年級上冊聽評課記錄《5-1豐富的圖形世界（第1課時）》
- 2024-2030年中國免疫細胞存儲行業(yè)市場發(fā)展分析及競爭形勢與投資戰(zhàn)略研究報告
- 工貿(mào)行業(yè)企業(yè)安全生產(chǎn)標準化建設(shè)實施指南
- T-CACM 1560.6-2023 中醫(yī)養(yǎng)生保健服務(wù)（非醫(yī)療）技術(shù)操作規(guī)范穴位貼敷
- 2024年全國統(tǒng)一考試高考新課標Ⅱ卷數(shù)學(xué)試題（真題+答案）
- 人教版小學(xué)數(shù)學(xué)一年級下冊第1-4單元教材分析
- JTS-215-2018碼頭結(jié)構(gòu)施工規(guī)范
- 財務(wù)實習(xí)生合同
- 2024年長沙衛(wèi)生職業(yè)學(xué)院單招職業(yè)適應(yīng)性測試題庫含答案
- 2024山西省文化旅游投資控股集團有限公司招聘筆試參考題庫附帶答案詳解
- 地質(zhì)災(zāi)害危險性評估的基本知識
- （正式版）SHT 3075-2024 石油化工鋼制壓力容器材料選用規(guī)范
評論
0/150
提交評論